SCHEMBL97201

SCHEMBL97201

O=COc1cc(F)c(F)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
TUBB1 Q9H4B7 1/20 0.31
CA1 P00915 2/20 0.30
CA2 P00918 2/20 0.30
CA4 P22748 1/20 0.30
MAOB P27338 1/20 0.30
CA12 O43570 1/20 0.30
CA7 P43166 1/20 0.30
CA13 Q8N1Q1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24445655 0.81 ERN1 (0.42)
SCHEMBL17404939 0.79 ANPEP (0.38)
SCHEMBL15588320 0.79 ERN1 (0.43)
SCHEMBL18573171 0.78 ALDH1A1 (0.32)
SCHEMBL2005178 0.77 CES2 (0.35) CES2CES1CA1CA12
SCHEMBL1256906 0.76 SOS1 (0.30)
SCHEMBL1995730 0.76 MAOB (0.43) CES2CES1MAOB
SCHEMBL1995536 0.75 ALDH1A1 (0.36) CES2CES1CA1CA2CA4
SCHEMBL19943297 0.75 CES2 (0.32) CES2CES1TUBB1
SCHEMBL91852 0.73 CES2 (0.43) CES2CES1TUBB1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
US-9645467-B2 Electrophoretic particles, electrophoretic dispersion liquid, display sheet, display device, and electronic equipment SEIKO EPSON CORPORATION (JP) 2017-05-09 US disclosed
US-20150205180-A1 METHOD OF MANUFACTURING ELECTROPHORESIS DISPERSION LIQUID, ELECTROPHORESIS DISPERSION LIQUID, DISPLAY DEVICE AND ELECTRONIC APPARATUS SEIKO EPSON CORPORATION (JP) 2015-07-23 US disclosed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US disclosed
US-20140376081-A1 ELECTROPHORETIC PARTICLES, ELECTROPHORETIC DISPERSION LIQUID, DISPLAY SHEET, DISPLAY DEVICE, AND ELECTRONIC EQUIPMENT E INK CORPORATION 2014-12-25 US disclosed
CN-102186921-B Fluorine-containing copolymer composition and process for production thereof ASAHI GLASS CO LTD 2014-01-15 CN disclosed
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-2338935-B1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF ASAHI GLASS CO LTD (JP) 2012-12-12 EP disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20110172336-A1 FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS ASAHI GLASS COMPANY, LIMITED (JP) 2011-07-14 US disclosed
EP-2338935-A1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF ASAHI GLASS COMPANY, LIMITED (JP) 2011-06-29 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB CES2 4459/4885CES1 2322/4885TUBB1 1325/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 CES2 4704/4885CES1 2850/4885TUBB1 3644/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 CES2 4704/4885CES1 2850/4885TUBB1 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.